[go: up one dir, main page]

PE20171176A1 - Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina - Google Patents

Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Info

Publication number
PE20171176A1
PE20171176A1 PE2016002751A PE2016002751A PE20171176A1 PE 20171176 A1 PE20171176 A1 PE 20171176A1 PE 2016002751 A PE2016002751 A PE 2016002751A PE 2016002751 A PE2016002751 A PE 2016002751A PE 20171176 A1 PE20171176 A1 PE 20171176A1
Authority
PE
Peru
Prior art keywords
ceftaroline
bacterial infections
complicated
infections
compositions
Prior art date
Application number
PE2016002751A
Other languages
English (en)
Inventor
George Talbot
Dirk Thye
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171176(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20171176A1 publication Critical patent/PE20171176A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE A) CEFTAROLINA O UN PROFARMACO TAL COMO CEFTAROLINA FOSAMILO EN UNA CANTIDAD DE 200MG A 800MG; Y B) UN ADUCTO DE L-ARGININA EN UNA CANTIDAD MENOR DE 2%; EN DONDE DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS TALES COMO i) INFECCIONES COMPLICADAS DE LA PIEL Y SUS ESTRUCTURAS PRODUCIDAS POR STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PYOGENES, KLEBSIELLA PNEUMONIAE, ENTRE OTROS, Y ii) NEUMONIA BACTERIANA ADQUIRIDA EN LA COMUNIDAD PRODUCIDA POR STREPTOCOCCUS PNEUMONIAE, STAPHYLOCOCCUS AUREUS, HAEMOPHILUS INFLUENZAE, ENTRE OTROS
PE2016002751A 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina PE20171176A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14

Publications (1)

Publication Number Publication Date
PE20171176A1 true PE20171176A1 (es) 2017-08-22

Family

ID=43757152

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016002751A PE20171176A1 (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina
PE2012000354A PE20121819A1 (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000354A PE20121819A1 (es) 2009-09-21 2010-09-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Country Status (24)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003201A (es)
NI (1) NI201200045A (es)
PE (2) PE20171176A1 (es)
PH (1) PH12012500528A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP6023800B2 (ja) 2011-06-17 2016-11-09 アストラゼネカ アクチボラグ ｔｒａｎｓ−７−オキソ−６−（スルホオキシ）−１，６−ジアザビシクロ［３，２，１］オクタン−２−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
ES2323759T3 (es) * 2000-08-10 2009-07-24 Takeda Pharmaceutical Company Limited Compuesto de fosfonocefem.
WO2002093162A2 (en) * 2001-05-17 2002-11-21 Mcgill University Individualization of therapy with antibiotic agents
AU2003217676B2 (en) * 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
MX2010003112A (es) * 2007-09-21 2010-08-11 Astrazeneca Ab Formas de dosificacion solubles que contienen derivados de cephem adecuados para administracion parenteral.

Also Published As

Publication number Publication date
KR20120083344A (ko) 2012-07-25
PE20121819A1 (es) 2013-02-01
WO2011035305A1 (en) 2011-03-24
CO6531417A2 (es) 2012-09-28
AU2010295269A1 (en) 2012-04-12
SG178936A1 (en) 2012-04-27
GT201200082A (es) 2014-12-22
MX2012003411A (es) 2012-04-30
EP2480236A4 (en) 2013-04-17
US20150258126A1 (en) 2015-09-17
CL2012000694A1 (es) 2012-08-31
CR20120137A (es) 2012-05-28
PH12012500528A1 (en) 2019-06-14
BR112012006250B1 (pt) 2021-07-06
IL218349A0 (en) 2012-04-30
AU2010295269B2 (en) 2014-06-05
EA201200501A1 (ru) 2012-10-30
EA029149B1 (ru) 2018-02-28
BR112012006250A2 (pt) 2016-05-31
EP2480236A1 (en) 2012-08-01
US20110071114A1 (en) 2011-03-24
CA2774772A1 (en) 2011-03-24
CU20120048A7 (es) 2012-10-15
HN2012000585A (es) 2015-06-15
ECSP12011739A (es) 2012-05-30
ZA201202924B (en) 2012-12-27
MX2012003201A (es) 2012-05-08
DOP2012000077A (es) 2012-05-31
NI201200045A (es) 2012-11-02
US9629861B2 (en) 2017-04-25
CN102781451A (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
MX342563B (es) Composiciones para el cuidado de la piel.
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
MX2012011816A (es) Aplicaciones antibacterianas de nanofibras de poli-n-acetilglucosamina.
PH12016501512B1 (en) Treatment for resistant acne
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
MX2015006681A (es) Formulaciones de vancomicina estabilizadas.
PE20100260A1 (es) Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol
NZ778077A (en) Plinabulin compositions
MX366773B (es) Composicion topica para lavado para su uso en pacientes con acne.
MX363478B (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con piperidinilo antibacterianas.
UY32445A (es) Composicion y procedimiento para usar aminopiridinas
MX352553B (es) Composicion para el cuidado oral comprendiendo un compuesto de amadori.
PH12015501562A1 (en) Non-aqueous oral care compositions
AU2013408771A8 (en) Prebiotic oral care compositions containing an alkyl glycoside
PE20121819A1 (es) Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina
BR112015013071A8 (pt) solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida
AR093717A1 (es) Composiciones y metodos para el tratamiento de la caries dental
MX2013013079A (es) Composiciones que comprenden un agente antibacterial y tazobactam.
AR076910A1 (es) Un agente cosmetico de despigmentacion que comprende un carbohidrato de delta -tocoferilo
MX2013009230A (es) Composicion farmaceutica de diosmina y hesperidina y su uso en dolor neuropatico.
BR112015014145A2 (pt) compostos antibacterianos
AR084421A1 (es) Betametasona como agente antibacteriano
MX2012011250A (es) Composicion quimica que comprende antibiotico y compuesto con actividad bacteriostatica para uso en el tratamiento de enfermedades bacterianas en plantas.